[Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study].
The medical treatment of the pelvic endometriosis includes the hormonal therapy that attacks directly to the endometriosis lesions or indirectly it inhibits the endometrial proliferation and it induces atrophy through the estrogenic deprivation, or to inclination of a combination of these effects. The objective of the present study was to evaluate the effects of two gonadotrophin release analogs in the treatment of the endometriosis. 15 patients were studied in who the diagnosis settled down of endometriosis by means of laparoscope; these were formed two groups in aleatory form and there were administered to each one them nafarelin acetate in dose of 200 or 400 micrograms each 12 hours or goserelin acetate in dose of 3.6 mg every 21 days; the serum levels of the stimulating follicle, luteinizing, estradiol and prolactin hormones were determined at intervals of four weeks and the secondary effects of these drugs were reported. There were carried out a second look laparoscope in 10 patients. The statistical analysis was carried out by means of the test of hypothesis of Wilcoxon and X2. Inside those results were found that as much the nafarelin as the Goserelin are able to diminish the gonadotropins and estradiol serum levels. Both analogs are effective for the control of the endometriotic lesions. The secondary symptoms are smaller and better supported by the patients using nafarelin. In conclusion as much the nafarelin as the goserelin are appropriate medications for the treatment of the pelvic endometriosis and the election between one or another one can settle down for the comfort of application, secondary effects and cost.
Calvo Lugo
G E
GE
Servicio de Biología de la Reproducción Humana, CMN 20 de Noviembre ISSSTE, México, D.F.
Sauceda González
L F
LF
Jiménez Perea
M L
ML
Díaz Arias
F J
FJ
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy*; D017273:Goserelin / Q000627:therapeutic use*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D017274:Nafarelin / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D006728:Hormones; D017273:Goserelin; D017274:Nafarelin